Compare DCI & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCI | ALKS |
|---|---|---|
| Founded | 1915 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 8.7B |
| IPO Year | 2005 | 2012 |
| Metric | DCI | ALKS |
|---|---|---|
| Price | $86.44 | $40.21 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 19 |
| Target Price | ★ $100.40 | $56.28 |
| AVG Volume (30 Days) | 577.0K | ★ 2.3M |
| Earning Date | 12-03-2026 | 10-27-2026 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | ★ 26.23 | N/A |
| EPS | ★ 3.85 | N/A |
| Revenue | ★ $2,844,900,000.00 | $1,475,899,000.00 |
| Revenue This Year | $7.86 | $23.54 |
| Revenue Next Year | $4.88 | $6.53 |
| P/E Ratio | $22.66 | ★ N/A |
| Revenue Growth | ★ 4.05 | N/A |
| 52 Week Low | $79.61 | $27.00 |
| 52 Week High | $112.84 | $55.67 |
| Indicator | DCI | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 41.21 | 37.87 |
| Support Level | $85.82 | $39.84 |
| Resistance Level | $87.80 | $43.22 |
| Average True Range (ATR) | 1.53 | 1.11 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 13.16 | 25.71 |
Donaldson is a leading manufacturer of filtration systems and replacement parts, including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors. The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.9 billion in revenue in its fiscal year 2026.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.